PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab

Proprotein convertase subtilisin/kexin type 9 (PCSK9) increases low-density lipoprotein cholesterol (LDL-C) concentrations through interference with normal physiologic hepatic LDL receptor (LDLR) recycling. Inhibiting PCSK9 results in improved LDLR recycling, increased LDLR availability on hepatocyt...

Descripción completa

Detalles Bibliográficos
Autores principales: Blom, Dirk J, Dent, Ricardo, Castro, Rita C, Toth, Peter P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4868869/
https://www.ncbi.nlm.nih.gov/pubmed/27274264
http://dx.doi.org/10.2147/VHRM.S102564

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4868869/
https://www.ncbi.nlm.nih.gov/pubmed/27274264
http://dx.doi.org/10.2147/VHRM.S102564

Ejemplares similares